Javelin Pharmaceuticals Inc (JAV)

[banna]

TORADOL annual sales are about $400 MIL ,as a generic & with its side effects. Dyloject ,has a patent (in EUROPE) & perhaps less side effects. When all this settles out could DYLOJECT potentially take 25%-50% of TORADOLS annual sales ?

Which suggests $100 -200 million annually from DYLOJECT alone.
What could ERESKA earrning potential be ?

Anyway ,just Say someone decides to buy JAV for about $3.50 a share or ABOUT $210 mil. They could perhaps make $100 -200 million a year off DYLOJECT till 2024 (supposing a U.S. patent of 2024 which is the European patent experation).

Over the life of the patent , DYLOJECT could make them perhaps about 1.2 -2.4 billion alone.

And what ever is made off of ERESKA would ju$t be extra gravy.